Title
MK-2870-020
Host/Owner
Dr Geraldine O’Sullivan Coyne
Location(s)
Mater Misericordiae Hospital
Eligibility
Has recurrent or metastatic cervical cancer.
Inclusion criteria
- Has histologically-confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix.
- Has recurrent or metastatic cervical cancer: That has progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab). -AND- Participants must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens.
Exclusion criteria
- Received systemic therapy, including single-agent IO, in the second-line (or subsequent) setting.
- Received prior treatment with a TROP2-targeted ADC.
- Received prior treatment with a topoisomerase I inhibitor-containing ADC.
- Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before study intervention administration.
Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
Clinical description
A Randomized, Open-Label, Phase 3 Trial of MK2870 vs Investigator's Choice Chemotherapy in Second Line Recurrent or Metastatic Cervical Cancer
